

PROFESSIONAL INFORMATION

Complementary Medicine Health Supplement
This unregistered medicine has not been evaluated by SAHPRA for its quality, safety or intended use.

SCHEDULING STATUS: S0**1 NAME OF THE MEDICINE**

BEROCCA PERFORMANCE MIXED BERRY Effervescent Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each effervescent tablet contains the following active ingredients:

Ingredient Name	Quantity
Vitamin B ₁ (Thiamine hydrochloride)	12 mg
Vitamin B ₂ (Riboflavin-5-Phosphate)	15 mg
Vitamin B ₃ (Nicotinamide)	50 mg
Vitamin B ₅ (Calcium pantothenate)	23 mg
Vitamin B ₆ (Pyridoxine hydrochloride)	8,2 mg
Vitamin B ₇ (d-Biotin)	150 µg
Vitamin B ₁₂ (Cyanocobalamin)	10 µg
Folic acid	400 µg
Vitamin C (Ascorbic Acid)	500 mg
Calcium (Calcium carbonate)	100 mg
Magnesium (Magnesium carbonate & Magnesium sulphate)	100 mg
Zinc (Zinc citrate)	10 mg

Sugar free.

Contains sweeteners: Acesulfame potassium 20 mg/tablet and Sucralose 15mg/tablet.

For full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Effervescent tablet.

Round, flat, speckled, reddish to dark pink tablet, which dissolves in water with effervescence, giving a red solution with an odour of tutti frutti.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

The combination of vitamin B-complex, vitamin C and minerals works in synergy to provide you with the essential micro-nutrients for sustained mental performance and physical well-being.

4.2 Posology and method of administration

Posology

For oral use.

Adults and adolescents: One (1) effervescent tablet daily dissolved in a glass of water (approximately 200 ml).

The recommended daily dose of one tablet per day must not be exceeded unless under supervision of a doctor, pharmacist or other healthcare professionals.

4.3 Contraindications

- Hypersensitivity to any of the active substances or to any of the excipients listed in section 6.1,
- Hypercalcaemia,
- Severe hypercalciuria,
- Severe renal insufficiency (GFR < 30ml/min) including individuals on dialysis,
- Hyperoxaluria,
- Nephrolithiasis or history of nephrolithiasis.

4.4 Special warnings and precautions for use

Vitamin C may interfere with testing kits and meters that measure glucose levels resulting in false readings.

Overdose of vitamin C in individuals with glucose-6-phosphate dehydrogenase deficiency (> 3 g in children and > 15 g in adults) has been associated with haemolytic anaemia.

This product is not formulated for the treatment of vitamin B12 deficiency due to atrophic gastritis, disorder of the ileum or pancreas, and gastro-intestinal malabsorption of vitamin B12 or intrinsic factor deficiency.

Intake of the product should be separated from other medications by 4 hours unless otherwise specified.

The levels of calcium and magnesium in the product contribute to the recommended daily intake, but the intake of the product at the labelled dose as the only source of calcium and magnesium cannot be regarded as sufficient for the treatment of calcium and/or magnesium deficiencies, or for the therapeutic functions of these elements apart from their role as cofactors in the activation and action of B vitamins.

4.5 Interaction with other medicines and other forms of interaction

Manifold potential interactions are reported in the literature for the single ingredients, thus individuals receiving any other medication, dietary/food supplements, or those under

medical care should consult a physician or health care professional before use of the product. When used as recommended no specific interactions are expected.

Drug interactions

Active Ingredient	Medicine	Description
Vitamin C	Desferrioxamine	Vitamin C may enhance tissue iron toxicity, especially in the heart, causing cardiac decompensation.
	Cyclosporine	Antioxidant supplementation including vitamin C may reduce cyclosporine blood level.
	Disulfiram	Chronic or high doses of vitamin C may interfere with the effectiveness of the disulfiram.
	Warfarin	High dose vitamin C may interfere with the effectiveness of warfarin.
Vitamin B ₆	Levodopa	Pyridoxine enhances the metabolism of levodopa, reducing its ant parkinsonism effects. However, this interaction does not occur when carbidopa is in combination with levodopa.
Vitamin B ₁₂	Chloramphenicol	Chloramphenicol may delay or interrupt the reticulocyte response to vitamin B ₁₂ . Therefore, blood counts need to be closely monitored if this combination can't be avoided.
Folic Acid	Methotrexate	Folic acid supplementation may reduce the effectiveness of methotrexate in the treatment of acute lymphoblastic leukaemia, and theoretically, the efficacy in the treatment of other cancers.
Calcium	Thiazide Diuretics	Thiazide diuretics reduce the urinary excretion of calcium. Due to an increased risk of hypercalcemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.
Magnesium, Zinc	Potassium-Sparing Diuretics	Potassium-sparing diuretics also have magnesium-sparing and/or zinc-sparing properties. Increased magnesium and/or zinc levels could result with concomitant use of potassium-sparing diuretics and supplementation.
Calcium, Magnesium, Zinc	Tetracycline antibiotics	Polyvalent cations, such as calcium, magnesium, and/or zinc, form complexes with certain substances resulting in decreased absorption of both substances. Separate intake of the product either 2 hours before or 4 hours after other medication, unless otherwise specified, will minimize risk for this interaction.
	Quinolone antibiotics	
	Penicillamine	
	Biphosphonates	
	Levothyroxine	
	Methyldopa	
	Mycophenolate mofetil	
	Eltrombopag	

Lab interactions

Because vitamin C is a strong reducing agent (i.e. electron donor), it can cause chemical interference in laboratory tests that involve oxidation-reduction reactions, such as the analyses of glucose, creatinine, uric acid, and inorganic phosphates in urine, serum and of occult blood in faeces. Using specific tests that are not dependent on reducing properties or discontinuing extra dietary vitamin C will avoid any undesirable interference. Refer to the manufacturer's information to determine if ascorbic acid interferes with the test.

Vitamin C may interfere with tests that measure urinary and blood glucose resulting in false readings, although it has no effect on blood glucose levels. Refer to the package insert of the meter or testing kit to determine if vitamin C (ascorbic acid) interferes and guidance for accuracy in readings.

4.6 Fertility, pregnancy and lactation**Fertility**

There is no evidence suggestive that normal endogenous levels of the vitamins and minerals in the product cause adverse reproductive effects in humans.

Pregnancy

The product is generally considered safe during pregnancy or lactation when taken as labelled. However, since there are no sufficient controlled human studies assessing the risk of product treatment during pregnancy or lactation, the product should only be used in pregnancy or lactation when clinically indicated and recommended by a doctor or healthcare professional.

The labelled dose should not be exceeded since chronic overdose might be harmful to the foetus and neonate. Allowance should be made for intake of the vitamins and minerals from all other sources.

Breastfeeding

The vitamins and minerals in the product are excreted into breast milk. This should be taken into consideration.

4.7 Effects on ability to drive and use machines

The product has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Berocca Performance Mixed Berry may have side effects.

Immune system disorders

Frequency unknown: Hypersensitivity reactions or anaphylaxis. Symptoms may include difficulty breathing or swallowing, angioedema, itchy throat, skin reddening, rash.

Gastrointestinal disorders:

Rare: abdominal discomfort, constipation, nausea, diarrhoea, vomiting

Renal and urinary disorders

Rare: A slight orange-yellow discolouration of urine may be noticed.

This effect is harmless and is due to the vitamin B₂ contained in the preparation.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are requested to report any suspected adverse drug reactions to SAHPRA via the Med Safety APP (Medsafety X SAHPRA) and eReporting platform (who-umc.org) found on SAHPRA website. Alternatively, you can report to Bayer SafeTrack site (<https://www.safetrack-public.bayer.com>)

4.9 Overdose

There is no evidence that this product can lead to an overdose when used as recommended. General manifestation of overdose may include confusion and gastrointestinal disturbances such as constipation, diarrhoea, nausea, and vomiting. If such symptoms occur, the product should be stopped, and a healthcare professional should be consulted for treatment of clinical manifestations.

Vitamin C

Acute or chronic overdose of vitamin C (> 2 g / day in adults) may significantly elevates serum and urinary oxalate levels. In some instances, this results in hyperoxaluria, calcium oxalate crystalluria, calcium oxalate deposition, kidney stone formation, tubulointerstitial nephropathy, and acute renal failure. Chronic consumption of high doses of ascorbic acid (> 500 mg / day in adults) may exacerbate iron overload and result in tissue damage in patients with hemochromatosis. Overdose of vitamin C in individuals with glucose-6-phosphate dehydrogenase deficiency (> 3 g / day in children and > 15 g / day in adults) may result in oxidative haemolysis or disseminated intravascular coagulation.

Vitamin B₆

Intake above UL (> 60 mg in adolescents 12 of age and 100 mg/day in adults) increases risk of sensory axonal neuropathy. Central effects have also been described. Neuropathy has been most commonly reported after chronic ingestion of 200 to 6000 mg/day for months or years.

The neuropathy gradually improved in all cases, following removal of pyridoxine. Irreversible destruction of sensory ganglion cells (neuronopathy) may also occur after a single extremely large parenteral dose, but the exact toxic amount is not well documented in humans.

Zinc

Zinc overdose (> 40 mg / day in adults) can cause diarrhoea, irritation, and corrosion of the gastrointestinal (GI) tract, acute renal tubular necrosis, interstitial nephritis, copper deficiency, sideroblastic anaemia and myeloneuropathies.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacological classification: category D 34.12 (Multiple substance formulation).

Biotin:

Biotin is traditionally considered to be a vitamin B substance. It is an essential coenzyme in fat metabolism and in other carboxylation reactions.

Calcium:

Calcium is indispensable for the growth and development of bones and teeth and for the functioning of the nervous system, processes also dependent on vitamin C and the B vitamins. Calcium deficiency is extremely common, and any supplementation of this mineral is therefore important to avoid damage to bones and teeth.

Pantothenic acid (Vitamin B₅):

Pantothenic acid is an integral part of coenzyme A, a critical molecule in a variety of reactions such as in fatty acid metabolism. It is involved in the intermediary metabolism of carbohydrate, fats and protein leading to energy release, synthesis of fatty acids and steroids and glycogenesis.

Ascorbic Acid (Vitamin C):

Vitamin C is required for the synthesis of collagen, an important structural component of blood vessels, tendons, ligaments, and bone. In addition, vitamin C is required for the synthesis of carnitine, a small molecule that is essential for the transport of fat to mitochondria, for conversion to energy.

Vitamin C is also a highly effective antioxidant. Even in small amounts - vitamin C can protect molecules in the body, such as proteins, lipids (fats), carbohydrates, and nucleic acids (DNA and RNA), from damage by free radicals and reactive oxygen species.

Vitamin B₁ (Thiamine):

Thiamine acts as a coenzyme in carbohydrate metabolism. An important function of thiamine pyrophosphate (TPP) is in oxidative decarboxylation of α -keto acids, pyruvate, and α -keto-glutarate. These steps are relevant to operation of the Krebs cycle, a major source of adenosine triphosphate (ATP) generation. Thiamine pyrophosphate is also used in protein catabolism, e.g. during decarboxylation of ketoacid analogues of branched chain amino acids (valine, isoleucine, and leucine). Although less than 10 % of glucose is metabolized via the transketolase re-action, it is the only way the body can produce ribose for RNA synthesis. This pathway also supplies reduced NADP for various synthetic reactions, e.g. fatty acid synthesis and steroid hydroxylation.

Vitamin B₂ (Riboflavin):

The function of riboflavin is to form the prosthetic groups of several enzyme systems (so-called flavoproteins) concerned with the oxidation reactions of tissue respiration. Thus, riboflavin is present in all cells as functioning compounds and not as stored materials.

Nicotinamide (Niacin):

Nicotinic acid and nicotinamide are biologically equivalent, and both are referred to as niacin (vitamin B₃). The primary function of niacin, in the form of nicotinamide adenine dinucleotide (NAD) and its phosphate (NADP), is to participate in oxidation-reduction reactions in co-operation with a large number of dehydrogenases. These reactions include glycolysis, synthesis of high energy phosphate compounds, pyruvate metabolism, and pentose biosynthesis. NAD and NADP also function in lipid and protein metabolism.

Vitamin B₆ (Pyridoxine):

Chemical compounds that have vitamin B₆ activity are the alcohol (pyridoxol), the aldehyde (pyridoxal), and the amine (pyridoxamine). Vitamin B₆ is rapidly converted by the liver into the metabolically active forms, pyridoxal phosphate (PLP) and pyridoxamine phosphate. These compounds are distributed throughout animal tissues but none are stored. The function of vitamin B₆, primarily as PLP or rarely as pyridoxamine phosphate is to act as a cofactor for an exceptionally large number of enzymes involved in synthesis or catabolism of amino acids.

LP is also required for the synthesis of δ -aminolevulinic acid, a precursor of heme. A large percentage of body vitamin B₆ is found in phosphorylase, the enzyme which converts glycogen to glucose-1-phosphate. Approximately one-half the vitamin B₆ found in the body can be accounted for in the phosphorylase of skeletal muscle.

Vitamin B₁₂ (Cyanocobalamin):

Vitamin B₁₂ is required for the function of the folate-dependent enzyme, methionine synthase. This enzyme is required for the synthesis of the amino acid methionine from homocysteine. Methionine in turn is required for the synthesis of S-adenosylmethionine, a methyl group donor used in many biological methylation reactions, including the methylation of a number of sites within DNA and RNA.

Folic Acid:

Folate coenzymes act as acceptors and donors of one-carbon units in a variety of reactions critical to the metabolism of nucleic acids and amino acids. Deficiency of the vitamin leads to impaired cell division and to alterations in protein synthesis, effects most noticeable in rapidly growing tissues.

Magnesium:

Magnesium is an essential body electrolyte. It is the second most important in intracellular fluid, is a co-factor in numerous enzyme systems, is involved in phosphate transfer, muscle contractility, neuronal transmission, and is believed to be essential for the structural stabilization of nucleic acids in large therapeutic dosages.

Zinc:

Zinc is an essential nutrient and plays an important role in maintenance of human health. It is important in cellular growth and differentiation with profound effects on the immune system, in collagen synthesis, and in antioxidant defense. Zinc has antioxidant capacity and contributes to the protection of cells from the damaging effects of reactive oxygen radicals and reactive nitrogen species produced during processes such as immune activation. The catalytic function of zinc is required for biological activity of more than 300 enzymes and zinc enzymes are found in all six International Union of Biochemistry (IUB) classes. In addition to its role in many enzymes, zinc helps to stabilize the structures of membranes, RNA, DNA, and ribosomes.

5.2 Pharmacokinetic properties

Biotin:

Absorption:

Biotin is absorbed in the intestine by a saturable, sodium dependent transporter. The transport of biotin was examined in different areas of the human small intestine and was found to be saturable in the presence of a sodium gradient but was linear in the presence of a choline gradient. Transport by the sodium-dependent process was noted to be higher in the duodenum than the jejunum, which was in turn higher than that in the ileum, and it was concluded that the proximal part of the human small intestine was the site of maximum transport of biotin.

Distribution:

For the evaluation of biotin nutritional status in humans, the circulating levels of the vitamin in whole blood, plasma, or serum and the urinary biotin excretion are employed. These levels are assessed mainly by microbiological methods and the great variation in the reported values can be due, in both urine and blood, to the analytical method. Reported values for circulating blood levels seem to range from (mean $\pm$ SD) 934 $\pm$ 385 to 4781 $\pm$ 2174 pmol biotin /liter. A circulating level in blood, plasma, or serum of around 1500 pmol/liter seems to indicate an adequate supply for biotin in humans.

Biotin serves as a prosthetic group in a number of enzymes in which the biotin moiety functions as a carboxyl carrier, i.e. enzymes that transport carboxyl units and fix carbon dioxide in animal tissue. The biotin-dependent enzymes can be divided into carboxylases (e.g. pyruvate carboxylase, acetyl-CoA carboxylase, etc.), transcarboxylase (methylmalonyl-CoA carboxyl-transferase), and decarboxylases (methylmalonyl-CoA decarboxylase, oxaloacetate decarboxylase). Tissues containing biotin-dependent enzymes include liver, kidney, brain and heart. The activities of the biotin-dependent enzymes in the various tissues are rapidly restored on administration of the vitamin to deficient animals. The rate of restoration of activities differs for the different tissues; it is fastest in kidney and brain and slower in liver and heart.

This might be indicative of differences in the availability of the vitamin to the various tissues or the rates at which the holoenzymes are synthesized.

Metabolism:

Any investigation into the metabolism of biotin in animals and humans is complicated by the fact that biotin-producing microorganisms exist in their intestinal tract distal to the cecum.

There are indications that in plasma part of the circulating biotin is bound to proteins.

Biotinidase was found to be the only protein in human serum that exchanges [3H](+)-biotin, and thus biotinidase could be the major carrier of biotin in plasma, and as such function in

biotin transport. Very little is known about biotin catabolism. The mammal does not seem able to degrade the ring system of biotin. In the urine of healthy human's small amounts of biotin metabolites have also been detected, none of which were biotinsulfoxide or biotin sulfone. The catabolism of biotin-containing holocarboxylases can lead to biocytin, from which biotin can be liberated by biotinidase, leading to an endogenous recycling of biotin.

Excretion:

Quite large day-to-day variations in fecal biotin excretion have been found, but excretion in feces is always greater than in urine. From the available data, a biotin level in urine of approximately 160 nmol per 24 hour or 70 nmol/liter seems to indicate an adequate supply of biotin for humans.

Calcium:

Absorption:

The amount of calcium absorbed depends on its interaction with other dietary constituents, and on physiological factors such as calcium-regulating hormones and stage of the life span. In general, the absorption of calcium supplements is better if they are taken with a meal. This may be because the meal stimulates gastric secretion and delays emptying, so that the calcium sources are better dispersed and dissolved. There are two routes of calcium absorption in the intestine. One is an active, saturable, transcellular process that occurs mainly in the duodenum and proximal jejunum and is regulated by vitamin D. Ileal absorption may also be affected by vitamin D status. The other pathway of calcium absorption is a passive, non-saturable, paracellular route that is independent of vitamin D regulation and occurs throughout the small intestine. The amount of calcium absorbed by this way depends primarily on its quantity and availability in the diet. Intakes above as little as 3 mmol (120 mg) in a meal will probably be absorbed passively by the small intestine. Most calcium absorption occurs in the ileum, where food remains for the longest time.

Distribution:

Because more than 99 % of the body's calcium is in bone, the skeleton is the major storage site for the maintenance of extracellular fluid (ECF) calcium. In the short term, negative calcium balance involves a harmless mobilization of bone calcium. In the longer term, the chronic removal of skeletal calcium has adverse effects on bone strength. The level of ionized calcium in plasma is controlled by an integrated response of the calcium-regulating hormones that affect calcium transport in the intestine, bone and kidney. Of these the most important are parathyroid hormone (PTH), calcitonin and vitamin D. Serum calcium by inhibiting bone resorption and agents that have a resorptive effect on bone. These include PTH, vitamin D metabolites and vitamin A. The most active vitamin D metabolite is 1,25(OH)₂D. In calcium deficiency more 1,25(OH)₂D is produced, causing enhanced intestinal absorption and renal absorption of calcium, and increased bone formation as well as resorption. The 1 % extra skeletal calcium is found in extracellular fluids, intracellular structures, and cell membranes.

Metabolism:

Calcium has a structural role in bone and teeth. Bone calcium is relied upon to maintain ECF calcium concentrations, which in turn are necessary for normal neuromuscular and other functions. The extracellular calcium plays an essential role in such vital functions as nerve conductance, muscle contraction, blood clotting, and membrane permeability.

Excretion:

Calcium is excreted in approximately equal amounts in urine and endogenous secretions. Calcium loss from the skin is only 0,4 mmol per day (15 mg per day), although this will increase substantially with increased sweating.

Pantothenic acid (Vitamin B₅):**Absorption:**

Pantothenic acid is thought to be absorbed principally in the jejunum by passive diffusion, although animal data suggest that low amounts may be absorbed by an active process.

Absorption seems to decrease when ingestion approaches levels of ten-times the recommended amounts in supplements. From the blood, uptake by heart, muscle and liver occurs by active transport, whereas uptake in the central nervous system, adipose tissue, and kidneys is by facilitated diffusion.

Distribution:

High concentrations (2-4 mg per 100 g) of pantothenic acid are found in liver, kidney, brain, and heart. Examination of the organs of rats revealed that, next to the liver, the adrenal gland contained the highest concentration of coenzyme A, suggesting a close relationship between pantothenic acid level and adrenal cortex function. Pantothenic acid is found in whole blood, plasma, serum, and red blood cells. The majority of the vitamin exists in the red blood cells as coenzyme A, and the serum reportedly contains no coenzyme A but does contain free pantothenic acid. Levels of pantothenic acid in the red blood cells are higher than levels of pantothenic acid in the plasma, and also red blood cells are more affected by dietary pantothenic acid. Total pantothenic acid levels below 100 µg/dl may be indicative of low levels of pantothenic acid in the diet. Total pantothenic acid content of whole blood for men of different age groups ranged from 94,0 to 117,4 µg/dl, and for women from 87,1 to 109,6 µg/dl.

Metabolism:

Pantothenic acid plays its primary physiological roles as a component of the coenzyme A molecule and within the 4'-phosphopantetheine moiety of the acyl carrier protein (ACP) of fatty acid synthetase, which serves in acyl-group activation and transfer reactions. These reactions are important in the release of energy from carbohydrates; in gluconeogenesis; in the synthesis and degradation of fatty acids; in the synthesis of such vital compounds as sterols and steroid hormones, porphyrins, and acetylcholine; and in acylation reactions in general. Pantothenic acid deficiency notably affects the adrenal cortex, the nervous system, skin, and hair.

Excretion:

Free pantothenic acid is excreted in the urine.

Ascorbic Acid (Vitamin C):**Absorption:**

Ascorbic acid is widely absorbed from the gastrointestinal tract. Ascorbic acid is absorbed primarily in the upper part of the small intestine via sodium-dependent active transport. When ascorbic acid is present in high concentrations, uptake occurs by means of passive diffusion. After oral administration of doses up to about 180 mg, 70-90 % of the substance is absorbed. With doses of 1-12 g, the proportion of ascorbic acid absorbed falls from approximately 50 % to about 15 %, though the absolute quantity of substance taken up continues to increase.

Distribution:

Plasma protein binding of ascorbic acid is approximately 24 %. Serum concentrations are normally 10 mg/l (60 μ mol/l). Concentrations below 6 mg/l (35 μ mol/l) indicate that the intake of vitamin C is not always adequate, and concentrations below 4 mg/l (20 μ mol/l) indicate that the intake is actually inadequate. In clinically manifest scurvy, serum concentrations are below 2 mg/l (10 μ mol/l).

Metabolism:

Ascorbic acid is metabolized partly via dehydroascorbic acid to oxalic acid. When ingested in excessive quantities, however, ascorbic acid is largely excreted in unchanged form in the urine and faeces. Ascorbic-acid-2-sulphate also appears as a metabolite in the urine.

Excretion:

The physiological body pool is about 1500 mg. The elimination half-life of ascorbic acid depends on the route of administration, the quantity administered and the rate of absorption.

Vitamin B₁ (Thiamine):

Absorption:

Thiamine is rapidly absorbed, largely in the proximal small intestine. There are two transport mechanisms, one by an active process at < 2 μ M, one by passive diffusion at > 2 μ M.

Distribution:

Average total amount of vitamin B₁ in adult humans is approximately 30 mg. High concentrations are found in skeletal muscle, heart, liver, kidney and brain. In the spinal cord and the brain, the thiamine level is about double that of peripheral nerves. The whole-blood thiamine varies from 5 to 12 μ g per 100 ml, 90 % of which is in the red cells and leukocytes. Leukocytes have a 10-fold higher concentration than red cells. Thiamine has a relatively high turnover rate in the body and is not stored in large amounts for any period of time in any tissue. Hence, a continuous supply is necessary. Relatively short periods of time with inadequate intake can lead to biochemical, followed by clinical, signs of deficiency. When the intake is about 60 μ g per 100 g body weight (or 42 mg per 70 kg) and the total body thiamine reaches 2 μ g/g (or 140 mg per 70 kg), a plateau is reached in most tissues.

Metabolism:

Oral (or parenteral) thiamine is quickly converted to the diphosphate and to a smaller extent the triphosphate esters in the tissues. All thiamine in excess of tissue needs and binding and storage capacity is rapidly excreted in the urine. Stimulation of nerves causes the release of thiamine or the monophosphate with a concomitant decrease in the tri- and diphosphates.

Excretion:

Vitamin B₁ is excreted in the urine. In addition to free vitamin B₁ and a small amount of thiamine diphosphate, thiochrome, and thiamine disulfide, about 20 or more metabolites of vitamin B₁ have been reported in the urine of rats and humans but only six have really been identified. The relative proportion of metabolites to vitamin B₁ excreted increases with decreasing vitamin B₁ intake.

Vitamin B₂ (Riboflavin):

Absorption:

Riboflavin is readily absorbed, largely in the proximal small intestine. Absorption involves an active, saturable transport system. Free riboflavin is phosphorylated to riboflavin 5'-phosphate (or FMN: flavin mononucleotide).

FMN then enters the portal system, where it is bound to plasma albumin and transported to the liver, where it is converted to FAD (flavin adenine dinucleotide).

Distribution:

Riboflavin and FMN are converted to FAD in the tissues where binding to specific flavoproteins occurs. The liver, the major site of storage, contains about one-third of the total body flavins. The liver, kidney, and heart have the richest concentrations of this vitamin, and 70-90 % is in the form of FAD. Free riboflavin constitutes less than 5 % of the stored flavins. In the human brain, the riboflavin content is higher in the basal ganglia and temporal cortex than in the frontal cortex.

Metabolism:

In tissues, FAD can be hydrolyzed to FMN and free riboflavin by phosphates and nucleotidases. Flavins bound to protein are resistant to hydrolysis, and this probably accounts for the fact that significant stores of flavin remain in the livers of animals that die of riboflavin deficiency.

Excretion:

Riboflavin is excreted primarily in the urine, with bile and sweat as minor routes of excretion. Studies of turnover rate of riboflavin in normal rat tissue have shown that the half-life is about 16 days. Riboflavin is excreted primarily unchanged, since no decomposition product has been found in either tissues or urine. The urinary excretion of riboflavin is about 200 µg per 24 hours in normal adults. In riboflavin deficiency this decreases to 40-70 µg per 24 hours.

Nearly all of a large oral dose of riboflavin is excreted in the urine of normal adults. The peak of excretion occurs within 2 hours. This becomes visible in individuals who take a dose of riboflavin, either in a vitamin pill or in enriched foods in following way. After about 2 hour the color of urine will change from straw color to an orange-yellow hue.

Nicotinamide (Niacin):

Absorption:

Niacin is the generic term that includes both nicotinic acid and nicotinamide. Both vitamins are absorbed by facilitated diffusion at low concentrations and by passive diffusion at higher concentrations, and both appear in blood plasma. Even large doses (24,6 mmol (3 g) or more) of niacin are efficiently absorbed from the intestine.

Distribution:

Niacin is rapidly removed from blood plasma by the tissues, particularly the liver and red cells; in the post absorption state only, small amounts remain in plasma. Once niacin enters the cell it is converted to its coenzyme forms, nicotinamide adenine dinucleotide (NAD) and NAD phosphate (NADP). In addition to NAD bound to enzymes, NAD not attached to an apoenzyme may also be present. This free NAD is sometimes designated as 'storage' NAD. In the rat, high concentrations of NAD are found in heart, liver, kidney, and muscle tissue.

Metabolism:

In the liver, any excess of free niacin that accumulates is methylated to N1-methyl-nicotinamide (NMN) by N-methyl transferase. The hydrolysis of hepatic NAD stores to nicotinamide and adenosine diphosphate ribose (ADPR) is of particular importance in niacin metabolism because it allows the release of nicotinamide for transport to and absorption by tissues needing niacin. The hydrolysis of NAD (and NADP) in the liver and other tissues is catalyzed by two classes of enzymes, the NAD glycohydrolases and the poly (ADPR) polymerases. The activity of these enzymes

appears to account in large measure for the rapid turnover of the pyridine nucleotides. Some bound forms of NAD, however, are relatively immune to glycohydrolase action. The NAD of glyceraldehyde 3-phosphate dehydrogenase is one example thus ensuring that the glycolysis pathway will be spared to some extent in niacin deficiency states.

Excretion:

NMN is the major niacin metabolite excreted in the urine. Other metabolites found in urine include the oxidized derivatives of NMN, 2- and 4-methyl pyridone, and nicotinuric acid, the conjugate of nicotinic acid and glycine.

The oxide and hydroxyl forms of niacin are also excreted in small amounts.

Vitamin B₆ (Pyridoxine):

Absorption:

Vitamin B₆ is readily absorbed via the gastrointestinal tract after oral doses. Vitamin B₆ comprises three chemically, metabolically, and functionally related forms: the alcohol pyridoxine (pyridoxol, PN), the aldehyde pyridoxal (PL), and the amine pyridoxamine (PM). The various dietary forms of vitamin B₆ are absorbed by intestinal mucosal cells through a nonsaturable process.

Distribution:

The B₆ forms are converted in the liver, erythrocytes and other tissues to pyridoxal phosphate (PLP) and pyridoxamine phosphate (PMP). These compounds are distributed throughout animal tissues but none are stored. A large percentage of body vitamin B₆ is found in phosphorylase, the enzyme that converts glycogen to glucose-1-phosphate. Approximately half the vitamin B₆ found in the body can be accounted for in the phosphorylase of skeletal muscle. PLP is present in the plasma as a PLP-albumin complex and in erythrocytes in association with hemoglobin. The PL concentration in the erythrocyte is up to four to five times greater than that in plasma.

Metabolism:

PLP and PMP act primarily as coenzymes in transamination reactions; primarily PLP acts as a cofactor for an exceptionally large number of enzymes involved in the synthesis or catabolism of amino acids. PLP also participates in decarboxylation and racemization of α -amino acids, in other metabolic transformations of amino acids, and in the metabolism of lipids and nucleic acids. In addition, it is the essential coenzyme for glycogen phosphorylase. Pyridoxal phosphate is also required for the synthesis of δ -aminolevulinic acid, a precursor of heme.

Excretion:

The phosphoric acid esters of the active forms of vitamin B₆ undergo hydrolysis before release from the cells. PL can be further oxidized to pyridoxic acid and other inactive oxidation products, which are then excreted in the urine.

Folic Acid:

Absorption:

Folic acid is rapidly absorbed from the gastrointestinal tract, mainly from the duodenum and jejunum and it is stated that folates have about half the bioavailability of crystalline folic acid.

Distribution:

The total content of folate in the liver has been estimated from biopsies and autopsy material to 6-14 mg, and total body folate to approximately 22 mg (range 15-30 mg).

Reserves are relatively low, also indicated by an overall half-life of about 100 days. Approximately two-thirds of folate in the plasma is protein bound, mainly as 5-methyl THF. The normal plasma concentration of folate is about 7-17 ng/mL, mainly represented by 5-methyl THF monoglutamate. After uptake of folate by the cells, mediated by a specific membrane bound protein, folate is stored in the cells after demethylation as the polyglutamate.

Metabolism:

The results of studies that were carried out indicate that further that about 1 % of the total folate body pool/day is catabolized or excreted. Long nutritional intervention is required to achieve a new steady-state.

Excretion:

Urinary excretion of intact folate, which is not associated to protein, is minimal, also due to the efficient re-absorption in the proximal tubuli (10-20 % of absorbed folate). Fecal folate excretion occurs but it is difficult to estimate due to microbial synthesis in the intestine. The main route of folate catabolism is cleavage resulting in pteridines and para-amino benzoylglutamate which is excreted as the N-acetyl compound in the urine.

Vitamin B₁₂ (Cyanocobalamin):

Absorption:

Cobalamins can be absorbed by two different mechanisms.

- An active mechanism (intrinsic factor mediated). The active mechanism is mediated by an intrinsic factor, a glycoprotein secreted by the parietal cells of the gastric mucosa. It is of primary importance in the absorption of physiological doses of cobalamin (approximately 1-5 µg).
- A diffusion-type mechanism (non-intrinsic factor mediated). The diffusion-type mechanism is operative when the amount of vitamin is large, usually in excess of the amount available from the diet. About 1 % of an oral dose of 100 µg and more of cobalamin is absorbed in pernicious anemia patients.

Distribution:

In plasma and tissue, the predominant forms are methylcobalamin, adenosyl cobalamin, and hydroxycobalamin. Methylcobalamin constitutes 60-80 % of the total plasma cobalamin. In normal human subjects, cobalamins are found principally in the liver, where the average amount is 1,5 mg. The kidneys, heart, spleen, and brain each contain about 20-30 µg. Mean values for the total body content calculated for human adults range from 2 to 5 mg.

The pituitary gland has the greatest concentration per gram of tissue of any organ.

Adenosylcobalamin is the major cobalamin in all the cellular tissues, constituting about 60-70 % in the liver and about 50 % in the other organs.

Metabolism:

In crossing the intestinal mucosa, vitamin B₁₂ is transferred to the plasma transport protein transcobalamin II, which delivers the vitamin to cells. The specific biochemical reactions in which the cobamide coenzymes participate are of two types: (1) those that contain 5'-deoxyadenosine linked covalently to the cobalt atom (adenosyl cobalamin), and (2) those that have a methyl group attached to the central cobalt atom (methyl cobalamin). The coenzyme methyl cobalamin catalyzes a transmethylation from a folic acid cofactor to homocysteine to form methionine. This reaction releases the unmethylated folate cofactor for other single carbon transfer reactions important to nucleic acid synthesis. The other cobalamin coenzyme, deoxyadenosylcobalamin,

catalyzes the conversion of methylmalonyl-coenzyme A to succinyl-coenzyme A, a reaction in the pathway for the degradation of certain amino acids and odd-chain fatty acids.

Excretion:

Excretion occurs via urinary, biliary, and fecal routes. These are the main excretion pathways. Only the unbound plasma cobalamin is available for urinary excretion and, therefore, urinary excretion by glomerular filtration of free cobalamin is minimal, varying up to 0,25 µg per day. Approximately 0,5-5 µg of cobalamin is secreted into the alimentary tract per day, mainly in the bile, of which at least 65-75 % is reabsorbed in the ileum by means of the intrinsic factor mechanism.

Magnesium:

Absorption:

Absorption of magnesium as a function of intake appears curvilinear. The curved portion is compatible with a saturable process (facilitated diffusion or active absorption) and the linear function reflects passive diffusion. Passive diffusion has been estimated to contribute around 7-10 %. Intestinal perfusion techniques in human subjects indicate magnesium to be absorbed by both jejunum and ileum with absorption being fully saturable in the ileum but not the jejunum.

Distribution:

More than half the total body magnesium is found in bone (60-65 %) with almost all the rest in soft tissue: muscle 27 %, other cells 6-7 %, extracellular < 1 %. The greater proportion of intracellular magnesium exists in bound form, e.g. in muscle mainly bound to adenosine triphosphate (ATP), phosphocreatine and myosin. Average plasma magnesium concentration is about 0,85 mM (range 0,65 to 1,0 mM) and is maintained remarkably constant in healthy individuals by poorly understood homeostatic controls, which do not appear to be regulated by hormonal mechanism.

Metabolism:

There a number of biochemical and physiological processes require or are modulated by magnesium. As the Mg-ATP2- complex, magnesium is important for all biosynthetic processes, for glycolysis, formation of cyclic-AMP (adenosine monophosphate), energy-dependent membrane transport, and transmission of the genetic code. More than 300 enzymes are known to be activated by magnesium.

Excretion:

Magnesium is retained either for tissue growth (including bone) or as turnover replacement; the remainder is excreted in the urine. Plasma magnesium levels are believed to be regulated primarily by the kidney. Approximately 70 % of plasma protein is not bound to protein and is therefore filterable.

About 30 % of filtered magnesium is reabsorbed in the proximal tubule and another 65 % is reabsorbed in the loop of Henle, the site at which major adjustments in response to plasma concentrations appear to take place.

Zinc:

Absorption:

The vast majority of ingested zinc is absorbed by the small intestine through a transcellular process with the jejunum being the site with the greatest transport rate. Only small amounts are absorbed in the stomach and large intestine. Absorption kinetics appear to be saturable,

and there is an increase in transport velocity with zinc depletion. Transfer from the intestine is via the portal system with most newly absorbed zinc bound to albumin.

Distribution:

The total body zinc content is controlled in part by regulating the efficiency of intestinal absorption and the excretion from endogenous zinc pools. As intraluminal concentrations of zinc rise, the fractional absorption of zinc decreases, but the actual amount of zinc absorbed rises linearly. Endogenous faecal zinc losses can be increased several fold to maintain zinc homeostasis with high intake of zinc.

Metabolism:

A two-component model best explains the elimination of absorbed zinc from the body. In humans, the initial rapid phase has a half-life of 12,5 days, and the slower turnover phase has a half-life value of about 300 days. The initial rapid half-life primarily represents liver uptake of circulating zinc and its release. The slower turnover rate reflects differing rates of zinc turnover in various tissues other than the liver. Zinc uptake by the central nervous system and bones is relatively slow. The pancreas, liver, kidney, and spleen have the most rapid rates of accumulation and turnover; uptake and exchange of zinc in the red blood cells and muscle are slower than in the viscera.

Excretion:

The major route for endogenous zinc excretion is into the gastrointestinal tract with ultimate loss in the faeces. Secretion of endogenous zinc into the small intestine is believed to be primarily via pancreatic exocrine secretions and possibly the intestinal mucosa. A percentage of this endogenous zinc is reabsorbed, which is essential to maintain hemostasis. When tracer doses of zinc are given either orally or intravenously, only about 2 % to 10 % is recovered in the urine; the remainder is lost in the faeces.

5.3 Preclinical safety data

There is no specific study with this product but the preclinical safety of the individual components has been extensively documented.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Citric acid

Sodium hydrogen carbonate

Tutti fruity flavour (composed of nature identical flavouring substances adsorbed on maltodextrin.)

Sodium carbonate

Sodium chloride

Beetroot concentration (maltodextrin, beetroot red E162, citric acid E330 and ascorbic acid E300)

Berry microfine (maltodextrin, vegetable juice colour beet E162, ascorbic acid E300 and citric acid E330)

Acesulfame potassium¹

Sucralose¹

Isomalt
Sorbitol

¹ sweetener

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store at or below 25°C.

Keep the container tightly closed, in order to protect from moisture.

6.5 Nature and contents of container

15 effervescent tablets packed in a rigid tube fitted with a plastic stopper with a desiccant in an integrated stopper. Tube(s) are packed in a secondary packaging (folding carton), with an enclosed leaflet or leaflet printed inside the box.

Pack sizes: 15 and 30 effervescent tablets.

6.6 Special precautions for disposal

No special requirements.

7 HOLDER OF CERTIFICATE OF REGISTRATION

Bayer (Pty) Ltd.
Collaboration Hub, 1st Floor
Waterfall Circle, 9 Country Estate Drive
Waterfall City, Midrand
South Africa
Co Reg. no.: 1968/011192/07
Tel: +27 11 921 5000

8 REGISTRATION NUMBER(S)

To be confirmed upon registration.

9 DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION

To be confirmed upon registration.



10 DATE OF REVISION OF TEXT

TBC

11 DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION

To be confirmed upon registration.

Manufactured by: Bayer Indonesia, Cimanggis Plant, Jalan Raya Jakarta Bogor Km 32 Cisalak, Kec. Sukmajaya, Kota Depok, Jawa Barat, Indonesia.
--